Initially developed for ulcerative colitis, GMA has since demonstrated immunomodulatory effects in conditions such as Crohn’s disease, rheumatoid arthritis, and dermatologic disorders, by depleting activated myeloid cells and altering cytokine profiles, reducing tumor necrosis factor (TNF)-α, interleukin (IL)-6, and increasing IL-10. The gene discussed is TNF; the disease is rheumatoid arthritis.